Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study

Vesikari, Timo; Karvonen, Aino; Prymula, Roman; Schuster, Volker; Tejedor, Juan Carlos; Cohen, Robert; Meurice, François; Han, H.H.; Damaso, Silvia; Bouckenooghe, Alain

doi:10.1016/s0140-6736(07)61744-9

Cited by 600 publications

(468 citation statements)

References 25 publications

Supporting

Mentioning

424

Contrasting

Unclassified

Order By: Relevance

“…9 RV5 and RV1 have proven highly efficacious and effective in industrialised countries, providing at least 90% protection against severe rotavirus gastroenteritis and at least 74% protection against rotavirus gastroenteritis of any severity. [18][19][20][21][22][23][24] In contrast, studies conducted in low-income countries in Africa and Asia revealed that the efficacy of the 2 vaccines ranged from 56% to 64% in protecting against severe rotavirus gastroenteritis. [25][26][27][28][29][30] In addition, in these settings vaccine efficacy waned between the first and second years after immunisation.…”

Section: Introductionmentioning

confidence: 99%

Options for improving effectiveness of rotavirus vaccines in developing countries

Tissera

Cowley

Bogdanovic-Sakran

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Rotavirus gastroenteritis is a leading global cause of mortality and morbidity in young children due to diarrhea and dehydration. Over 85% of deaths occur in developing countries. In industrialised countries, 2 live oral rotavirus vaccines licensed in 2006 quickly demonstrated high effectiveness, dramatically reducing severe rotavirus gastroenteritis admissions in many settings by more than 90%. In contrast, the same vaccines reduced severe rotavirus gastroenteritis by only 30-60% in developing countries, but have been proven life-saving. Bridging this "efficacy gap" offers the possibility to save many more lives of children under the age of 5. The reduced efficacy of rotavirus vaccines in developing settings may be related to differences in transmission dynamics, as well as host luminal, mucosal and immune factors. This review will examine strategies currently under study to target the issue of reduced efficacy and effectiveness of oral rotavirus vaccines in developing settings.

show abstract

Section: Introductionmentioning

confidence: 99%

Options for improving effectiveness of rotavirus vaccines in developing countries

Tissera

Cowley

Bogdanovic-Sakran

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…This strain was detected in five vaccinated infants and in eight unvaccinated control recipients. A European Rotarix phase III trial was carried out in six countries (Czech Republic, Finland, France, Germany, Italy and Spain) (Vesikari et al 2007). These studies demonstrated cross-protection against severe G2P[4] RV-A gastroenteritis (efficacy = 85.5%; 95% CI = 24-98.5) (Vesikari et al 2007).…”

mentioning

confidence: 99%

Group A rotavirus genotypes and the ongoing Brazilian experience: a review

Leite

Carvalho-Costa

Linhares

2008

Mem. Inst. Oswaldo Cruz

102

View full text Add to dashboard Cite

Brazil was the first Latin American country to introduce universal group A rotavirus (RV-A) vaccination in March 2006, resulting in a unique epidemiological scenario. Since RV-A first identification in Brazil, 2,691 RV-A-positive stool samples, collected between 1982- 2007, were typed by independent research groups throughout the country. In the pre-vaccination era, 2,492 RV-A-positive samples collected from 1982-2005 were successfully typed, while 199 samples were analyzed from 2006-2007. According to the reviewed studies, there were two important times in the pre-vaccination era: (i) the period from 1982-1995, during which the detection of G5P[8] RV-A, in addition to the classical genotypes G1-4, challenged vaccine development programs; and (ii) the period from 1996-2005, during which genotype G9P[8] emerged, following a global trend. The rate of G2P[4] RV-A detection decreased from 26% (173/653) during 1982-1995 to 2% (43/1,839) during 1996-2005. The overall detection rate of RV-A genotypes from 1982-2005 was as follows: 43% (n = 1,079) G1P[8]/G1P[not typed (NT)]; 20% (n = 488) G9P[8]/G9P[NT]; 9% (n = 216) G2P[4]/G2P[NT]; 6% (n = 151) G3P[8]/G3P[NT]; 4% (n = 103) G4P[8]/G4P[NT]; and 4% (n = 94) G5P[8]/G5P[NT]. Mixed infections accounted for 189 (7%) of the positive samples, while atypical G/P combinations or other genotypes, including G6, G8, G10 and G12, were identified in 172 (7%) samples. The initial surveillance studies carried out in several Brazilian states with RV-A-positive samples collected in 2006 and 2007 show a predominance of G2P[4] strains (148/199 or 74%). Herein, we review RV-A typing studies carried out since the 1980s in Brazil, highlighting the dynamics of RV-A strain circulation profiles before and early after universal use of RV-A vaccine in Brazil

show abstract

“…The low coverage rate is possibly explained by limited and specific age allowed for immunization, the 1 st dose is not beyond 3 months and of 2 nd dose is not later than 6 months. A study which had been done in Europe showed that two doses of rotavaccine provided high protection against any and severe rotavirus gastroenteritis, along with an overall reduction of admissions for gastroenteritis over two consecutive rotavirus epidemic seasons [20]. Most rotavirus positive cases found to have severe diarrheal disease.…”

Section: Pediatric Infectious Diseases: Open Access Issn 2573-0282mentioning

confidence: 99%

Rotavirus Diarrhea in Children Under Five in Basrah: Hospital Based Study

Habash¹,

Habeeb²

2018

Pediatric Infect Dis

View full text Add to dashboard Cite

show abstract

Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study

Cited by 600 publications

References 25 publications

Options for improving effectiveness of rotavirus vaccines in developing countries

Options for improving effectiveness of rotavirus vaccines in developing countries

Group A rotavirus genotypes and the ongoing Brazilian experience: a review

Rotavirus Diarrhea in Children Under Five in Basrah: Hospital Based Study

Contact Info

Product

Resources

About